BPC-157

BPC-157 (Body Protection Compound-157, also known as PL 14736) is a 15-amino-acid synthetic peptide derived from a larger protein found in gastric juice. It has become a heavily-marketed biohacker substance with substantial preclinical research and minimal human clinical data. BPC-157 is not FDA approved for any indication, and in September 2023 the FDA placed it on the Category 2 bulk drug substances list, prohibiting US compounding pharmacies from preparing it. In February 2026, HHS proposed removing it from Category 2, with final FDA determination pending a 2026 advisory committee review.

BPC-157's proposed mechanism is unclear even after thousands of animal studies. Candidate mechanisms in preclinical models include: upregulation of vascular endothelial growth factor (VEGF) and the angiogenic response at injury sites, modulation of nitric oxide pathways, effects on dopamine, serotonin, and growth hormone signaling, and interaction with the FAK/paxillin pathway in tissue remodeling. It's unusually stable, resistant to gastric degradation, and reports in animal models suggest systemic effects whether given orally, subcutaneously, or intraperitoneally — unusual for a peptide.

Preclinical research on BPC-157 spans over 35 years and several hundred studies, primarily from a single research group in Zagreb, Croatia led by Predrag Sikiric. Animal models report benefits across tendon, ligament, muscle, bone, GI, brain, and cardiovascular injury contexts. A 2025 narrative review (PMC) catalogued the evidence base and flagged the concentration of authorship as a methodological concern: most of the corpus originates from one laboratory ecosystem, and truly independent replication is limited. Human clinical trials are sparse. As of April 2026, no Phase 3 trial has reported for any indication.

No completed or ongoing Phase 3 trials for any human indication as of April 2026. Limited Phase 1/2 data exist, including a prior EU Phase 2 trial in inflammatory bowel disease (PL 14736) that did not advance. Some small US trials have been registered on ClinicalTrials.gov but none have produced publishable Phase 3 results.

Not FDA approved. Category 2 (Sep 2023), with February 2026 HHS proposal to remove. Compounding pharmacies cannot currently prepare it. Research-peptide vendors sell it with 'research use only' labeling; the FDA has issued warning letters to vendors who paired this labeling with dosing information or therapeutic claims. See our FDA timeline. Full regulatory timeline →

The central tension: BPC-157 has dramatic preclinical effects and enthusiastic off-label human adoption, but the peer-reviewed human evidence base is thin and heavily concentrated in one research lab. This is a classic setup for a compound to either become an FDA-approved drug after rigorous Phase 3 trials or quietly fade as rigorous evidence fails to materialize. The February 2026 HHS reclassification push — politically motivated per public reporting — adds regulatory uncertainty on top of clinical uncertainty.

• BPC-157 narrative review (PMC, 2025) →
• BPC-157 human clinical trials overview →
• FDA bulk drug substances — Category 2 list →